After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Aclaris Therapeutics Inc (ACRS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.11, or 2.21%, to $5.09. The Aclaris Therapeutics Inc has recorded 11,430 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202).
Stocks Info
ACRS belongs to the Healthcare sector of the NASDAQ while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $4.98 and fluctuated between $5.0200 as its day high and $4.5700 as its day low. The current market capitalization of Aclaris Therapeutics Inc is $352.53M. A total of 2.0 million shares were traded on the day, compared to an average of 928.76K shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ACRS has seen 3 BUY and 2 SELL insider trades, representing the acquisition of 25,195 and the disposition of 6,285 shares. Over the last 12 months, there were 27 BUYs and 24 SELLs from insiders. Insiders purchased 304,997 shares during that period but sold 225,456.
In the most recent transaction, Monahan Joseph sold 6,000 shares of ACRS for 5.08 per share on Oct 23. After the transaction, the Chief Scientific Officer now owns 129,724 company shares. In a previous transaction on Sep 06, Balthaser Kevin bought 9,490 shares at 7.90 per share. ACRS shares that Chief Financial Officer owns now total 15,461.
Among the insiders who bought shares, Loerop James acquired of 14,705 shares on Aug 28 at a per-share price of $6.80. This resulted in the Chief Business Officer holding 21,688 shares of ACRS after the transaction. In another insider transaction, Monahan Joseph sold 6,000 shares at $7.32 per share on Aug 21. Company shares held by the Chief Scientific Officer now total 135,724.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ACRS in the last 3 months, the mean price target is $29.67 with high estimates of $43.00 and low estimates of $20.00. In terms of 52-week highs and lows, ACRS has a high of $18.96 and a low of $4.33.
As of this writing, ACRS has an earnings estimate of -$0.48 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.44 per share and a lower estimate of -$0.52. The company reported an EPS of -$0.42 in the last quarter, which was 4.50% higher than expectations of -$0.44.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ACRS’s latest balance sheet shows that the firm has $225.66M in Cash & Short Term Investments as of fiscal 2021. There were $693.00k in debt and $22.93M in liabilities at the time. Its Book Value Per Share was $2.54, while its Total Shareholder’s Equity was $197.34M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACRS is Buy with a score of 5.00.
